24 completed, 5 unknown, 4 recruiting, 3 terminated. 12 Phase 2, 4 Phase 1, 4 Phase 3, 4 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 12 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 4 | Terminated 2, Completed 1, Unknown 1 |
| Not applicable | 1 | Terminated 1 |
Follow Pseudomonas Aeruginosa: new trials by email Literature Review of Pseudomonas Aeruginosa trials Research Report on Pseudomonas Aeruginosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa Osteomyelitis, Pseudomonas Infections | Recruiting | Centre Hospitalier de Saint-Denis | 300 | 2025-04-11 | 2025-07-09 | |
| Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa Pseudomonas Infections, Pseudomonas Aeruginosa | Recruiting | Centre Hospitalier Régional d'Orléans | 600 | 2025-03-11 | 2026-04-30 | |
| Pathobiomes in Gut of Critically Ill Patients P. aeruginosa using in vitro and in vivo assays - Pseudomonas Aeruginosa | Recruiting | University of Chicago | 100 | 2024-12-19 | 2026-02-02 | |
| PMT for MDRO Decolonization PMT - Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections | Phase 2 | Completed | University of Pennsylvania | 32 | 2024-08-19 | 2026-09-24 |
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection RSP-1502, Tobramycin inhalation solution - Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic | Phase 1 / Phase 2 | Completed | Respirion Pharmaceuticals Pty Ltd | 71 | 2024-04-01 | 2026-06-25 |
| Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3) Observation - Pseudomonas Aeruginosa, COVID-19 | Completed | Central Hospital, Nancy, France | 51 | 2023-12-01 | 2024-05-07 | |
| Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis Ceftolozane/tazobactam - Bronchiectasis, Cystic Fibrosis | Phase 4 | Unknown | Sunshine Coast Hospital and Health Service | 30 | 2023-10-01 | 2023-09-13 |
| Animal-Assisted Visitation Program Chlorhexidine Trial Chlorhexidine - Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile | Phase 4 | Completed | Johns Hopkins Bloomberg School of Public Health | 45 | 2023-05-01 | 2026-10-13 |
| Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection AP-PA02, Placebo - Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa | Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 48 | 2023-01-10 | 2026-01-05 |
| Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa culture on cetrimide agar, Staining with Gram stain, Antibiotic sensitivity testing - Pseudomonas Aeruginosa | Unknown | Sohag University | 75 | 2022-12-01 | 2023-04-12 | |
| Clinical Outcomes in Patients With Infection by Resistant Microorganism Pathogen resistant phenotype - Pneumonia, Bloodstream Infection | Unknown | Hospital Universitario Virgen Macarena | 5000 | 2022-10-01 | 2023-05-30 | |
| Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study. Pseudomonas Aeruginosa, Colonization, Asymptomatic | Completed | Erasmus Medical Center | 2105 | 2022-03-01 | 2026-03-10 | |
| Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections Duration of therapy - Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection | Not applicable | Terminated | Hospital Moinhos de Vento | 107 | 2022-01-27 | 2024-03-06 |
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis AP-PA02, Placebo - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 29 | 2020-12-22 | 2024-01-31 |
| Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies Isolation of anti-Pseudomonas antibodies from type B lymphocytes - Pseudomonas Aeruginosa, Multi-antibiotic Resistance | Recruiting | University Hospital, Grenoble | 30 | 2020-10-05 | 2025-11-20 | |
| Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center. Cystic Fibrosis, Pseudomonas Aeruginosa | Unknown | Queen Fabiola Children's University Hospital | 15 | 2019-02-06 | 2019-04-10 | |
| Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim, Ftortiazinon (tablets 300 mg) full dose + Maxipim, placebo+Maxipim - Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa | Phase 2 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 777 | 2018-10-17 | 2025-06-22 |
| Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease Microbial biofilm diagnose - Bronchiectasis, Microbial Colonization | Unknown | Hospital Clinic of Barcelona | 96 | 2018-03-01 | 2021-03-18 | |
| Targeted AntiBiotics for Chronic Pulmonary Diseases Piperacillin/tazobactam, Ciprofloxacin - COPD, Respiratory Tract Infections | Phase 4 | Terminated | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | 51 | 2018-01-10 | 2023-05-25 |
| Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections Ceftolozane-Tazobactam - Pseudomonas Infections, Pseudomonas Aeruginosa | Completed | Temple University | 200 | 2017-02-01 | 2026-05-22 |
Showing 20 of 37. Sign in to see all of them.
Pseudomonas Infections (37) · Cystic Fibrosis (18) · Bronchiectasis (3) · Infections (3) · Acinetobacter Infections (2) · Cross Infection (2) · Lung Diseases (2) · Pneumonia (2) · Respiratory Tract Infections (2) · Sepsis (2) · Urinary Tract Infections (2) · Asthma (1) · Asymptomatic Infections (1) · Bacteremia (1) · Bacterial Infections (1)
Bacterial Infections and Mycoses (37) · Bacterial Infections (36) · Gram-Negative Bacterial Infections (36) · Infections (34) · Respiratory Tract Diseases (24) · Lung Diseases (21) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Digestive System Diseases (18) · Genetic Diseases, Inborn (18) · Infant, Newborn, Diseases (18) · Pancreatic Diseases (18) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Disease Attributes (7) · Bronchial Diseases (4)
Aztreonam (2) · ceftolozane, tazobactam drug combination (2) · Amitriptyline (1) · Ceftazidime (1) · Chlorhexidine (1) · Ciprofloxacin (1) · Colistin (1) · Duration of Therapy (1) · Immunotherapy (1) · In Vitro Techniques (1) · Inhalation (1) · Observation (1) · Piperacillin, Tazobactam Drug Combination (1) · Staining and Labeling (1) · Tablets (1)
Gilead Sciences (4) · Armata Pharmaceuticals, Inc. (2) · Novartis Pharmaceuticals (2) · University Hospital, Grenoble (2) · University of Jena (2) · Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche (1) · Central Hospital, Nancy, France (1) · Centre Hospitalier Régional d'Orléans (1) · Centre Hospitalier de Saint-Denis (1) · Chronic Obstructive Pulmonary Disease Trial Network, Denmark (1) · Erasmus Medical Center (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Hospital Clinic of Barcelona (1) · Hospital Moinhos de Vento (1) · Hospital Universitario Virgen Macarena (1)
United States (14) · France (8) · Germany (4) · Spain (4) · Russia (3) · Australia (2) · Belgium (2) · Canada (2) · Estonia (2) · Italy (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Croatia (1) · Czechia (1)
Jochen Mainz, M.D. (2) · Alexander Mangushlo, MD (1) · Alexander Shvets, MD (1) · Alexandre Prehn Zavascki (1) · Andrew Burke, MBBS (1) · Andrey Gorelov, MD (1) · Annika Hollsing, MD, PhD (1) · Arnaud Florentin, Dr (1) · Ashot Yesayan, MD (1) · Brendan J Kelly (1) · Claire Wainwright, MD (1) · Dmitry Gorelov, MD (1) · Dominique Hubert, MD (1) · Ebtisam M Gad (1)
PMID 26709158, PMID 19635928, PMID 21441078, PMID 24596456, PMID 31238116, PMID 32671834, PMID 35124256, PMID 36380312, PMID 38102448, PMID 38844921, PMID 39695798, PMID 40187923, PMID 40691185
2008 (1), R01GM062344 (1), R01HD097692 (1)